不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
细胞因子诱导的杀伤细胞临床研究：来自淋巴瘤试验的经验教训
英文原题：Clinical Studies on Cytokine-Induced Killer Cells: Lessons from Lymphoma Trials.
查看英文原题
Clinical Studies on Cytokine-Induced Killer Cells: Lessons from Lymphoma Trials.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
癌症是一种复杂疾病，治疗耐药和复发常构成严重临床挑战；若癌症本身具有异质性，情况会更复杂，例如由淋巴细胞构成、包含70多种亚型的淋巴瘤。淋巴瘤治疗选择持续增加。本文介绍淋巴瘤中细胞因子诱导杀伤（CIK）细胞疗法的临床试验，以及其他在临床前淋巴瘤模型中将CIK细胞与协同靶向肿瘤的免疫模块联合、以增强治疗潜力的研究。从更广泛角度看，CIK细胞治疗具有潜力；在快速演变的癌症治疗领域，若能将其优化为个体化治疗方法，将有利于淋巴瘤治疗。
展开英文摘要原文
Cancer is a complex disease where resistance to therapies and relapses often pose a serious clinical challenge. The scenario is even more complicated when the cancer type itself is heterogeneous in nature, e. g. , lymphoma, a cancer of the lymphocytes which constitutes more than 70 different subtypes. Indeed, the treatment options continue to expand in lymphomas.
Herein, we provide insights into lymphoma-specific clinical trials based on cytokine-induced killer (CIK) cell therapy and other pre-clinical lymphoma models where CIK cells have been used along with other synergetic tumor-targeting immune modules to improve their therapeutic potential. From a broader perspective, we will highlight that CIK cell therapy has potential, and in this rapidly evolving landscape of cancer therapies its optimization (as a personalized therapeutic approach) will be beneficial in lymphomas.
论文信息
- 作者
- Zhang Y、Sharma A、Weiher H、Schmid M、Kristiansen G、Schmidt-Wolf IGH
- 单位
- Department of Integrated Oncology, Center for Integrated Oncology (CIO), University Hospital Bonn, 3127 Bonn, Germany.Germany
- 文献类型
- 综述
- 期刊
- Cancers2021 Nov 29
- 原文标识
- PubMed 34885117 · DOI 10.3390/cancers13236007
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →